302 related articles for article (PubMed ID: 24567197)
1. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
[TBL] [Abstract][Full Text] [Related]
2. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
5. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
7. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
10. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.
Warner E; Causer PA; Wong JW; Wright FC; Jong RA; Hill KA; Messner SJ; Yaffe MJ; Narod SA; Plewes DB
Breast J; 2011; 17(1):9-17. PubMed ID: 21251121
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
[TBL] [Abstract][Full Text] [Related]
13. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
14. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
16. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
17. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
Tilanus-Linthorst M; Verhoog L; Obdeijn IM; Bartels K; Menke-Pluymers M; Eggermont A; Klijn J; Meijers-Heijboer H; van der Kwast T; Brekelmans C
Int J Cancer; 2002 Nov; 102(1):91-5. PubMed ID: 12353239
[TBL] [Abstract][Full Text] [Related]
18. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
[TBL] [Abstract][Full Text] [Related]
19. Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
Pilewskie M; Zabor EC; Gilbert E; Stempel M; Petruolo O; Mangino D; Robson M; Jochelson MS
Breast Cancer Res Treat; 2019 May; 175(1):141-148. PubMed ID: 30673971
[TBL] [Abstract][Full Text] [Related]
20. Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.
Bosse K; Graeser M; Goßmann A; Hackenbroch M; Schmutzler RK; Rhiem K
Arch Gynecol Obstet; 2014 Mar; 289(3):663-70. PubMed ID: 24045978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]